TONIX PHARMACEUTICALS HOLDING CORP. Selling, General and Administrative Expense
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Selling, General and Administrative Expense of $35.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for the quarter ending 2026-06-30 was $35.96M, a 121.94% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for the quarter ending 2026-03-31 was $28.62M, a 183.29% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for the quarter ending 2025-12-31 was $35.68M, a 128.96% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for the quarter ending 2025-09-30 was $25.70M, a 233.48% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for fiscal 2025 was $87.68M, a 118.66% increase from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for fiscal 2024 was $40.10M, a 15.39% increase from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for fiscal 2023 was $34.75M, a 15.02% increase from fiscal 2022.
- TONIX PHARMACEUTICALS HOLDING CORP. selling, general and administrative expense for fiscal 2022 was $30.21M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.96M 10-Q · filed 2026-08-10 | $64.58M 10-Q · filed 2026-08-10 | $100.26M derived: sum of 3 quarters · filed 2026-08-10 | $125.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $28.62M 10-Q · filed 2026-05-11 | $64.30M derived: sum of 2 quarters · filed 2026-05-11 | $90.00M derived: sum of 3 quarters · filed 2026-05-11 | $106.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $35.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $61.38M derived: sum of 2 quarters · filed 2026-03-12 | $77.58M derived: sum of 3 quarters · filed 2026-08-10 | $87.68M 10-K · filed 2026-03-12 |
| 2025-09-30 | $25.70M 10-Q · filed 2025-11-10 | $41.90M derived: sum of 2 quarters · filed 2026-08-10 | $52.01M 10-Q · filed 2025-11-10 | $67.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $16.20M 10-Q · filed 2026-08-10 | $26.31M 10-Q · filed 2026-08-10 | $41.89M derived: sum of 3 quarters · filed 2026-08-10 | $49.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $10.10M 10-Q · filed 2026-05-11 | $25.69M derived: sum of 2 quarters · filed 2026-05-11 | $33.39M derived: sum of 3 quarters · filed 2026-05-11 | $40.90M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $15.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $23.29M derived: sum of 2 quarters · filed 2026-03-12 | $30.79M derived: sum of 3 quarters · filed 2026-03-12 | $40.10M 10-K · filed 2026-03-12 |
| 2024-09-30 | $7.71M 10-Q · filed 2025-11-10 | $15.21M derived: sum of 2 quarters · filed 2025-11-10 | $24.52M 10-Q · filed 2025-11-10 | $36.14M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $7.50M 10-Q · filed 2025-08-11 | $16.81M 10-Q · filed 2025-08-11 | $28.43M derived: sum of 3 quarters · filed 2025-08-11 | $37.15M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $9.31M 10-Q · filed 2025-05-12 | $20.93M derived: sum of 2 quarters · filed 2025-05-12 | $29.64M derived: sum of 3 quarters · filed 2025-05-12 | $36.67M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $11.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $20.33M derived: sum of 2 quarters · filed 2025-03-18 | $27.36M derived: sum of 3 quarters · filed 2025-03-18 | $34.75M 10-K · filed 2025-03-18 |
| 2023-09-30 | $8.71M 10-Q · filed 2024-11-12 | $15.74M derived: sum of 2 quarters · filed 2024-11-12 | $23.13M 10-Q · filed 2024-11-12 | $31.18M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $7.03M 10-Q · filed 2024-08-16 | $14.42M 10-Q · filed 2024-08-16 | $22.47M derived: sum of 3 quarters · filed 2024-08-16 | $29.86M derived: sum of 4 quarters · filed 2024-08-16 |
| 2023-03-31 | $7.39M 10-Q · filed 2024-05-13 | $15.45M derived: sum of 2 quarters · filed 2024-05-13 | $22.84M derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $8.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $15.44M derived: sum of 2 quarters · filed 2024-04-01 | $30.21M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $7.39M 10-Q · filed 2023-11-09 | $22.16M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |